SAN FRANCISCO--(EON: Enhanced Online News)--Gemmus Pharma, a biotechnology company developing improved treatments for infectious diseases, will present data at this year’s BIOInvestor Forum. The talk titled “GP1681: A New Host-targeted Influenza Therapy”, will be given by Daryl Faulds, Ph.D., Co-founder and CEO of Gemmus, on Tuesday October 8, at 8:45 am. The BIOInvestor Forum will be held at the Palace Hotel, San Francisco.
“Gemmus is pleased to have been invited to present the latest data on our ‘strain independent’ flu treatment candidate”
Gemmus has recently submitted a pre-IND package to the FDA with details on its lead candidate for the treatment of moderate-to-severe symptoms of flu. GP1681 is an innovative therapy that works by modulating the host response of the patient, in contrast to typical treatments that focus on attacking a specific virus. This new approach allows Gemmus’ candidate to improve the broad range of flu symptoms brought on by any influenza strain. Treatment with GP1681 has the potential for a faster return to normal activities than is possible with no treatment or with the administration of antiviral therapies.
“Gemmus is pleased to have been invited to present the latest data on our ‘strain independent’ flu treatment candidate,” said Daryl Faulds, PhD.
Results of the trials demonstrate that influenza-infected mice treated with GP1681 were protected against death compared to placebo-treated mice. The increased survival was due to a decrease in respiratory tract inflammation as demonstrated by a decrease in lung weight, lung disease score, lung pro-inflammatory cytokine levels and lung cellular infiltrates of influenza-infected mice. Protection with GP1681 does not affect the development of an adaptive immune response or limit the innate immune response.
Gemmus is a privately-held biotechnology company developing innovative pharmaceutical products for the treatment of infectious diseases by focusing on modulating the host response to disease. Gemmus was founded in 2007 to develop novel treatments for influenza based on EP2 and EP4 agonists, and in-licensed technology from a major pharmaceutical company. Gemmus has received SBIR(NIH) and QTDP competitive grants and is funded by a syndicate of angel groups led by the Life Science Angels (LSA). Gemmus is a member of the QB3 network, a San Francisco Bay Area Biotech incubator associated with UCSF Mission Bay campus. For more information and corporate background, please visit: www.gemmuspharma.com.
Forward Looking Statements
Statements included in this press release that are not a description of historical facts may be forward looking statements. The inclusion of forward looking statements should not be regarded as a representation by Gemmus that any of its plans will be achieved. Actual results may differ materially from those anticipated or set forth in this press release due to the risks and uncertainties inherent in Gemmus' business including, without limitation, statements about difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products, unexpected performance or side effects of its products, the scope and validity of its products’ patent protection, competition from other companies and its ability to obtain additional financing to support its operations. All forward looking statements are qualified in their entirety by this statement and Gemmus undertakes no obligation to revise or update this press release to reflect events or circumstances occurring after the date hereof.